Oncology Practice Management Issues


July 2017, Vol 7, No 7

Drug Pricing Under the Trump Administration

Meg Barbor, MPH

Health Policy

Washington, DC—A change in leadership brings with it healthcare reform and potential changes in drug pricing in the United States, said Jessica Turgon, MBA, Principal, ECG Management Consultants, Washington, DC, at the 2017 Association of Community Cancer Centers meeting. Ms Turgon discussed what this transition of power means for cancer centers, and what oncology providers can realistically expect under the Trump administration. [ Read More ]

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

Eileen Koutnik-Fotopoulos

ASCO Annual Report

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row. [ Read More ]

Slowing Down to Move Forward: The Summer of 2017 May Be Pivotal for Oncology Practices

Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

This year has been more hectic for practice administrators than I have seen in decades. Practice administrators keep telling me they feel they are working harder and harder, and have so many more demands on the practice involving reporting, chasing reimbursement, securing access for their patients, and helping their physicians navigate the increasing demands on them, that it is just too hard to keep up. [ Read More ]

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

Wayne Kuznar

ASCO 2017 Highlights

Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a poly ADP-ribose polymerase (PARP) inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 American Society of Clinical Oncology meeting. [ Read More ]

Novel Assay Provides 100 Times More Information than Current Liquid Biopsies for Early Cancer Detection

Phoebe Starr

ASCO 2017 Highlights

Chicago, IL—A new high-intensity genomic sequencing strategy (developed by Grail Inc) detects circulating tumor DNA (ctDNA) at a high rate. The new approach is a major improvement on previous tests using ctDNA, which focus on a limited number of driver mutations to inform treatment strategies for metastatic disease or to monitor disease burden. The new test offers ultra-deep sequencing with a broad genomic coverage, but it is not ready for prime time to detect occult cancer. At present, the test is a research platform and is not commercially available. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Leukemia

Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with leukemia for inclusion in investigations of new therapies or new regimens of existing treatments for patients with leukemia. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]